Trianz Solutions Announces Availability of Acceliant eClinical Suite V6.1
A key productivity enhancement in Acceliant V6.1 provides trial builders the ability to define and import CRF metadata in commonly available formats. This allows data managers and their staff to collaboratively design and deploy CRF’s hours after approval. In addition, changes to specifications can be re-imported with ease. This feature adds to the existing features for import of edit checks and test data, thus further reducing CRF development and deployment time.
Additionally, V6.1 enhances
• Support for Phase IV studies by increasing scalability and performance on a single server compared to previous versions of Acceliant.
• Export of extremely large data sets with on-the-fly compression
• Features to customize and improve import performance
• Reporting with additional report templates and use of custom filters in reports
• Table controls with custom row level reports (e.g. Adverse Events)
• The notification subsystem to notify user groups on subject events, edit check failures and other statuses in Acceliant.
• Computer based training capabilities
The Acceliant eClinical Suite also includes integrated modules for coding, document management, and trial administration to unmask the clinical trial process and provide clients complete visibility and access into the management of their clinical trial data. Acceliant supports Phase I to Phase IV trials, Registries, and post-marketing studies.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025